Organic Active Ingredients TRIZ Cases

This composition uses hypertonic saline and local delivery to limit systemic NSAID effects while targeting respiratory and oral pathogens.

This case examines route-specific 5-MeO-DMT dosing to address limited anxiety treatment effectiveness and compliance.

This case uses enteric coating and scored dose units to match three-times-daily efficacy with twice-daily dosing.

This case uses intravenous, intramuscular, or subcutaneous 5-MeO-DMT to address bipolar symptoms with rapid action and durable response.

CPI-818 selectively targets ITK to increase Th1 cells, limit Th2 cytokines, and address cancer, autoimmune disease, and allergies.

This case uses alpha-polyglutamated pralatrexate liposomes to improve tumor delivery, intracellular retention, and efflux resistance.

This case uses an IAP ligand, linker, and target ligand to improve degradation of intracellular kinases such as ROCK2 and FAK.

This case uses ABCB1 expression to guide tepoxalin treatment, turning a chemotherapy resistance mechanism into selective cancer-cell killing.

L-arginine or meglumine and selected excipients improve CCR3 antagonist stability during granulation and oral formulation manufacture.

This case uses subcutaneous IL-31RA antibody dosing at extended intervals to relieve pruritus while reducing medication and hospital visits.

Lysine cores, PEG chains, amide bonds, and click chemistry enable modular constructs with controlled targeting and effector combinations.

Microspheres help microneedles bypass the skin barrier, supporting sustained weekly release with short attachment times.

This case uses a twice-daily 9 or 18 mg PDE4B oral composition to address PF-ILD progression and gastrointestinal side effects.

This case combines EP4 antagonists with checkpoint antibodies, radiation, or antimetabolites to improve anti-tumor activity.

This case pairs CAPRIN-1 antibody therapy with a RET kinase inhibitor to boost phagocytosis and address secondary-mutation resistance.

Structural variations in new compounds inhibit NLRP3 inflammasome activity across immune, metabolic, autoimmune, and cancer disorders.

Vegetable lipid blends deliver DHA-rich omega-3 content with improved oxidative stability.

This case uses crystalline and amorphous Compound (I) forms to inhibit triple-mutant EGFR while limiting wild-type toxicity.

A defined first-lipid-to-sterol ratio supports mRNA and siRNA delivery while addressing toxicity concerns from amino-group lipids.

Mutation testing directs PKC inhibitor treatment for non-uveal melanoma and cancers including pancreatic, colorectal, and lung tumors.

Chemical modifications and GalNAc conjugation strengthen PCSK9 silencing, nuclease stability, and targeted liver delivery.

Pyrimidine compounds target influenza strains resistant to neuraminidase inhibitors.

HMO blends support athlete gut microbiota, immune function, and recovery.

This case uses budesonide, glycerin, and xanthan gum to localize corticosteroid delivery and reduce systemic side effects.

Amide-containing heterocyclic compounds target the PRMT5·MTA complex, inhibiting MTAP-deficient tumors while sparing wild-type cells.

Pyridine-triazole compounds inhibit PHD to stabilize HIFα and induce EPO.

Novel dihydrofuropyridine derivatives improve ROCK inhibitor selectivity and potency.

Gut-targeted NLRP3 antagonists address anti-TNFα resistance while limiting systemic infection risks.

Arginine, polysorbate 80, and pH control stabilize high-concentration BAN2401 formulations for intravenous administration.

This case uses glacial acetic acid to improve ketorolac yield and purity, then applies chiral amine or enzyme resolution for (R)-ketorolac.

This case combines azvudine with chemotherapy to improve tumor control, delay resistance, and reduce harm to normal tissues.

Two overlapping half-shells form a slit-like aperture, combining easier capsule production with stable, targeted mucosal drug release.

This case uses epigenetic regulation by beta-caryophyllene to restore water balance and reduce moisture loss in skin and mucosa.

DHM is combined with matrix materials and plasticizers in HME to improve absorption, stability, and prolonged release.

This case develops a thermally stable AAK1 inhibitor salt form for high-purity manufacture and pharmaceutical formulation.

Separate strands target sense and antisense C9orf72 transcripts, addressing incomplete silencing in mutation-associated ALS and FTD.

This case replaces costly reagents with salt metathesis and crystallization to improve yield, purity, and pharmaceutical suitability.

This case uses selective GDF/BMP antagonists to reduce pulmonary vascular remodeling, muscularization, and PH complications.

CRISPR-edited immune cells resist steroids and calcineurin inhibitors, helping Tregs survive and function during GVHD prophylaxis.

Explore riluzole prodrugs that resist hepatic metabolism and release riluzole in plasma for more predictable ALS treatment.

This case varies molecular substituents and ring systems to improve CGRP receptor antagonist activity and specificity for migraine.

This case uses ionizable, neutral, and sterol lipids to stabilize unshielded nanoparticles while reducing immunogenicity.

This case uses bisaminoquinolines and bisaminoacridines to block autophagy and potentially improve responses to anti-cancer agents.

A separate buffer with controlled pH and osmolality helps keep injectable DMT formulations stable during storage.

This peptide combines receptor-mediated barrier crossing with tumor recognition for brain tumor imaging and drug delivery.

A single-dose aerosol article and closed flow controller regulate heating to make aerosol delivery per puff more consistent.

Controlled 0.5–10 μm particles improve dry-powder dispersibility for lung delivery.

Atropisomeric ATM inhibitors improve kinase selectivity and reduce off-target effects.

This case examines furazidin for bacterial vaginosis, targeting Gardnerella and Atopobium while limiting Lactobacillus depletion.

High-affinity ligands deliver payloads into engineered cells to moderate therapy effects.

Antisense oligonucleotides induce exon skipping in PRDM15 mRNA, inhibiting expression while sparing normal tissue homeostasis.

Oil-in-water emulsion maintains solubility of benzoxazinone active ingredient in topical formulations.

Compound 512 activates the Wnt/beta-catenin pathway to rescue intestinal stem cells and promote epithelial repair.

Miglyol 812 acts as an intermediary to dissolve sonidegib, eliminating sedimentation and ensuring consistent dosing without mechanical agitation.

A specific antioxidant combination improves sperm quality parameters without altering hormonal levels.

Interleukin-10 reprograms CD8+ T cells to overcome complement-mediated immune suppression, improving treatment efficacy.

Oral pharmaceutical composition with specific P2X7 modulators resolves insufficient therapeutic effect by effectively regulating receptor activity.

Tetrandrine lowers beta-catenin and CaMKIIgamma to overcome T cell exclusion barriers in cancer treatment.

Low-dose brimonidine combinations with histamine antagonists reduce intraocular pressure while alleviating eye redness.

Danegaptide blocks connexin 43 hemichannels to reduce ATP leakage, lowering inflammation and fibrosis markers in chronic kidney disease.

DIM analogs scavenge free radicals to protect normal cells, resolving toxicity and timing constraints in radioprotection.

Disulfide linkers join cell-binding agents to cytotoxic maytansinoids, reducing off-target toxicity while maintaining therapeutic efficacy.

Mithramycin ketone and diketone derivatives modify ring C positions to selectively inhibit ETS transcription factors while reducing toxicity to non-Ewing cells.

Formula A-a bicycloamine benzenesulfonamides block Nav 1.7 channels selectively, minimizing side effects from non-specific channel inhibition.

Bead milled aripiprazole particles under 14.3 microns in an oral soluble film resolve low solubility and poor patient compliance issues.

NOP receptor partial agonists and antagonists address disrupted cerebral blood flow and secondary ischemic damage in traumatic brain injury treatment.

Administering sub-minimal dosages of EZH2 and checkpoint inhibitors reduces side effects while enhancing anti-tumor efficacy.

Cyclic urea-substituted quinoxaline piperidine compounds modulate the ORL-1 receptor, reducing opioid side effects while maintaining pain relief efficacy.

A photosensitive compound encapsulated within a biodegradable polymer nanoparticle provides controlled fluorescence emission for simultaneous imaging and therapy.

Ribozymes and endogenous ligase RtcB generate circular RNA aptamers that evade exonuclease degradation, enabling micromolar intracellular concentrations.

Replacing EDC/NHS chemistry with triazine coupling eliminates N-acylurea impurities while creating stable chondroitin hydrogels for soft tissue repair.

A cationic lipid and neutral lipid composition delivers mRNA into mammalian cells.

Non-steroidal pyridooxazepine compounds reduce side effects and cross-reactivity while maintaining therapeutic efficacy.

Oral capsinoids shrink prostate volume and improve urine flow, eliminating invasive catheterization procedures and adverse side effects.

Protic polar solvents extract procyanidin B2 from discarded seeds to treat metabolic syndrome.

Drug-loaded platelets transport anti-cancer agents to tumors, reducing systemic toxicity and protecting drugs from metabolic degradation.

Retrovirus-derived integrase enzymes induce double-stranded breaks in chromosomal DNA to trigger apoptosis in targeted cell populations.

Deuterium substitution in neuroactive steroids slows metabolic degradation, enhancing therapeutic potency and specificity for CNS conditions.

pH buffering agents maintain composition stability and prevent coloration during storage without additional antioxidants.

Acoustic mixing creates a high G-force environment to granulate drug substances without SiO2 excipients, improving flowability and bulk density.

Adjusting bulk solution pH to 4-5 with citric acid balances solubility and chemical stability during lyophilization.

Combination immunotherapy merges LAK, CIK, gamma delta T, and CTL cell populations to orchestrate broad anti-tumor immune responses.

Astragalus polysaccharide extract repolarizes tumor-associated macrophages to the M1 phenotype, reducing angiogenesis and metastasis.

Selective alpha-2 adrenergic agonists shrink spleen size without interfering with other physiological processes controlled by different adrenergic receptors.

Serum-free spheroid culture boosts TGFβ1 expression to overcome low treatment efficiency in cartilage repair.

A synthetic lipopeptide vaccine composition combines carbohydrate antigens with helper T-cell epitopes to induce robust immune activation.

A compressed tablet formulation uses a non-hygroscopic lipidic matrix to protect moisture-sensitive active agents from degradation.

A triphasic oral drug regimen delivers ethinylestradiol and cyproterone acetate in varying phases to maintain contraceptive efficacy.

Formula I lipids merge structural stability with tissue targeting to simplify complex multi-lipid formulations.

Aramchol amine salts resolve the contradiction between therapeutic efficacy and toxicity by enabling lower doses with improved absorption.

A composite nanofiber membrane uses PLGA and PDO fibers to achieve controlled drug release through electrostatic spinning.